MedTrace Logo

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

NCT04854499 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2025-11-19

Study results available
· View outcomes & findings →

Summary

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).

Conditions

Interventions

DRUG

Magrolimab

Administered intravenously

DRUG

Pembrolizumab

Administered intravenously

DRUG

Docetaxel

Administered intravenously

DRUG

5-FU

Administered intravenously

DRUG

Cisplatin

Administered intravenously

DRUG

Carboplatin

Administered intravenously

DRUG

Zimberelimab

Administered intravenously

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2024-10-02
Completion
2024-10-02
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Germany
  • Hong Kong
  • Italy
  • Poland
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854499 on ClinicalTrials.gov